Genetic diagnosis strategy of hereditary non-polyposis colorectal cancer

Jian-Qiu Sheng, Hong Zhang, Min Ji, Lei Fu, Hong Mu, Ming-Zhi Zhang, Ji-Sheng Huang, Min Han, Ai-Qin Li, Zhi Wei, Zi-Qin Sun, Zi-Tao Wu, Chang-Hong Xia, Shi-Rong Li

AIM: To study the characteristics of mismatch repair gene mutation of Chinese hereditary non-polyposis colorectal cancer (HNPPC) and hMLH1 gene promoter methylation, and to improve the screening strategy and explore the pertinent test methods.

METHODS: A systematic analysis of 30 probands from HNPPC families in the north of China was performed by immunohistochemistry, microsatellite instability (MSI), gene mutation and methylation detection.

RESULTS: High frequency microsatellite instability occurred in 25 probands (83.3%) of HNPPC family. Loss of hMLH1 and hMSH2 protein expression accounted for 88% of all microsatellite instability. Pathogenic mutation occurred in 14 samples and 3 novel mutational sites were discovered. Deletion of exons 1-6, 1-7 and 8 of hMSH2 was detected in 3 samples and no large fragment deletion was found in hMLH1. Of the 30 probands, hMLH1 gene promoter methylation occurred in 3 probands. The rate of gene micromutation detection combined with large fragment deletion detection was 46.7%-56.7%. The rate of the two methods in combination with methylation detection was 63.3%.

CONCLUSION: Scientific and rational detection strategy can improve the detection rate of HNPPC. Based on traditional molecular genetics and combined with epigenetics, multiple detection methods can accurately diagnose HNPPC.

Key words: Hereditary non-polyposis colorectal cancer; Gene mutation; Mismatch repair; hMSH2; hMLH1; Large fragment deletion; Methylation

INTRODUCTION

Hereditary non-polyposis colorectal cancer (HNPPC) is a dominant autosomal genetic syndrome caused by germ-line mutation of mismatch repair gene, accounting for 5%-10% of all colorectal cancer. Genetic linkage analysis and genetics show that about 80% of HNPPC are associated with germ-line mutation of hMLH1 and hMSH2. Most of these mutations are micromutation (also known as a point mutation), small fragment insertion or deletion, etc. Large fragment deletion in hMLH1 and hMSH2 (especially hMSH2) gene is another way of germ-line mutation. In addi-
tion, recent epigenetic studies indicate that CpG island methylation in hMLH1 gene promoter region is also a mechanism underlying gene inactivation and tumorigenesis[10]. Therefore, systematic and comprehensive detection analysis of 30 samples from HNPCC families in the north of China was performed using various methods.

MATERIALS AND METHODS

Materials
Between 2000 and 2002, 30 probands from HNPCC families were collected and registered by General Hospital of Beijing Military Command and other hospital in Henan, Hebei and Shandong Provinces, and Inner Mongolia Autonomous Region. All study methods were approved by the Ethics Committee of General Hospital of Beijing Military Command and the 30 probands from HNPCC families gave written consent to participate in the study. Twenty-one families were in line with Bethesda Guideline (BG) I, 7 families Bethesda Guideline III and 2 families Bethesda Guideline IV, respectively[11]. With probands as the core, HNPCC genealogical tree of at least two generations was drawn. Pedigree analysis was performed. Family member files including the age when the tumor was diagnosed, the relation to proband, tumor type and location, etc (including parenteral cancer) were established.

Methods
DNA extraction: Tumor and normal tissues were obtained from probands. Tumor tissue was fixed with for- malin, embedded in paraffin, cut into 6-μm thick sections which were stained with 0.1% methylthioninium chloride. The location (more than 80% tumor tissue) most suitable to microdissection was marked and microdissection was done. DNA was extracted from tumor and normal tissues with phenol/chloroform/isoamyl alcohol for microsatellite instability (MSI) and immunohistochemistry detection[12]. DNA was extracted from venous blood for gene mutation and methylation detection.

Microsatellite instability and immunohistochemistry detection: Microsatellite instability detection was performed in 5 microsatellite markers: D2S123, DSS346, BAT-25, BAT-26 and BAT-40[13,14]. For hMSH2 and hMLH1, immunohistochemical staining was done with the standard biotin-avidin-peroxidase complex method[15]. DNA was extracted from venous blood for gene mutation and methylation detection.

Microsatellite instability and immunohistochemistry detection: Microsatellite instability detection was performed in 5 microsatellite markers: D2S123, DSS346, BAT-25, BAT-26 and BAT-40[13,14]. For hMSH2 and hMLH1, immunohistochemical staining was done with the standard biotin-avidin-peroxidase complex method as previously described[13].

hMSH2 and hMLH1 gene mutation detection: Micromutation detection was performed in 25 samples with high microsatellite instability. PCR was performed to amplify all exons (including intron-exon junction) of hMSH2 and hMLH1. PCR products were sequenced with a DNA automatic sequencer (ABIPRISM 3730XL) to find micromutation in the samples and to determine their mutation type.

Large fragment deletion detection in hMSH2 and hMLH1: Multiplex ligation-dependent probe amplification (MLPA) technique[10] was used to detect large fragment deletion in the samples without micromutation with a hMLH1 and hMSH2 large fragment deletion kit purchased from MRC Holland Company. The major steps of MLPA technique include to probe hybridization with the target sequence and specific ligation, to amplify hMSH2 and hMLH1 by PCR with probes, and to analyze PCR products. The PCR products were applied to a ABI PRISM3730 sequencer containing 6% polyacrylamide gel for electrophoresis. The electrophoresis results were analyzed with GeneMapper 3.0 software. The peak of each exon was compared with that of control sample. If the relative height was reduced by 35%-55%, the fragment was determined to have exon deletion. If the relative height was increased by 30%-55%, the fragment was determined to have exon duplication. If the peak was 0, the fragment was determined to have homozygous deletion.

Methylation detection: hMLH1 gene promoter methylation detection was performed in 30 samples. First, DNA was sulfurized with an EZ DNA methylation-gold kit purchased from ZYMO RESEARCH Company, and then methylation-specific PCR (MSP)[17] was performed. PCR amplification was performed twice for each sample with methylation and non-methylation primers, respectively. PCR products were applied to a 10% non-denaturing polyacrylamide gel for electrophoresis, then stained with ethidium bromide, and observed under an ultraviolet lamp.

RESULTS

Clinical and pathological information and family history
Of the 30 families, 21 were in line with BG I, 7 were in line with BG III and 2 were in line BG IV (Table 1). One hundred and forty tumors were found in 106 of the 708 members in these families. Of the 140 tumors, 22 (15.7%, 22/140) were extracolonic cancers. Of the 22 tumors, 7 were gastric cancers which are the most common type of extracolonic cancer. Of the colon cancers, 86 (72.9%, 86/118) were right colon cancers and 32 (27.1%, 32/118) were left colon cancer. One patient had synchronous multiple-primary cancers and 7 had metachronous multiple-primary cancers.

Microsatellite instability analysis and mismatch repair protein expression
Microsatellite instability analysis and mismatch repair protein expression in probands are shown in Table 1. Of the 30 samples detected, high frequency microsatellite instability (MSI-H) occurred in 25 samples (83.3%), low frequency microsatellite instability (MSI-L) in one sample (3.3%) and microsatellite stability (MSS) in 4 samples (13.3%). Of the 5 microsatellite loci, MSI-H expression rate was 100% (25/25) and 96% (24/25) in BAT-25 and BAT-26, respectively. Of the 25 samples with MSI-H, loss of hMLH1 or hMSH2 protein expression occurred in 22 (88%), loss of hMLH1 protein expression occurred in 12, and loss of hMSH2 protein expression in
respectively. No loss of mismatch repair protein expression was found in the other 8 samples.

**DNA sequencing**

Of the 25 samples with MSI-H, pathogenic mutation (Table 1) was detected in 14 (56%). Of the 14 samples, hMLH1 and hMSH2 gene mutation occurred in 9 and 5, respectively. The detection rate of micromutation was 46.7% (14/30). Three novel mutational sites were discovered. Of the 3 novel mutations, a frame shift mutation at c.503_4insA was located in hMLH1, and another frame shift mutation at c.899_890insAT and a splicing mutation at IVS7-1G→A, SA of Exon 8 were located in hMSH2. A new base replacement (hMSH2, c.2583A→G) was detected in sample H10, which did not cause changes in amino acid sequence. There was no co-segregation phenomenon between this base replacement and disease in its family, suggesting that it is a new change in polymorphism.

**Large fragment deletion detection**

Electrophoresis scanning peaks in exons 1-6, 1-7 and 8 of hMSH2 in 3 samples were reduced by over 35% (Figure 1), demonstrating that these exons have deletions which are heterozygotic in nature. Large fragment deletion was not detected in hMLH1. Large fragment deletion in hMSH2 accounted for 37.5% of all hNSH2 pathogenic mutations and 17.6% of total hMLH1 and hMSH2 mutations, respectively. Of the 30 samples, micromutation and large fragment deletion were detected in 17, the detection rate of combined methods was 56.7% (17/30).

**Methylation detection**

hMLH1 gene promoter methylation occurred in 3 of the 30 samples. The detection rate of combined micromutation, large fragment deletion and methylation detection was 63.3% (19/30). MSP electropherogram (Figure 2) showed that hMLH1 gene promoter methylation occurred in 3 samples. Exhaustive methylation occurred in 2 of the 3 samples with their electropherograms displaying M specific fragment but no U deletion, and partial methylation occurred in one of the 3 samples with its electropherogram displaying M and U fragments. Only U specific fragment occurred in the other samples, indicating that no methylation occurs in these samples.

**DISCUSSION**

Germ-line mutation of mismatch repair gene is the molecular genetic basis of HNPCC pathogenesis. Mismatch repair gene mutation may lead to truncation

---

**Table 1 Detection results in 30 probands from HNPCC families**

| Family | Bethesda guidelines | MSI | Expression of MMR proteins | Micromutation/polymorphism²/large fragment deletion | hMLH1 gene promoter methylation |
|--------|---------------------|-----|-----------------------------|---------------------------------------------------|--------------------------------|
| H1     | BG1                 | MSI-H | +                           | +                                                 |                                |
| H4     | BG1                 | MSI-H | -                           | + hMSH2 exon13 | IVS13-2 A→C (9A of Exon 14) | u |
| H9     | BG1                 | MSI-H | -                           | + hMSH2 exon5 | c.610G→T (G201stop) | u |
| H17    | BG1                 | MSI-H | +                           | + hMSH2 exon5 | c.899_890insAT | u |
| H22    | BG1                 | MSI-H | +                           | + hMSH2 exon7 | IVS7-3G→A (5A of Exon 8) | u |
| H10    | BG1                 | MSI-H | +                           | + hMSH2 exon5 | c.2583A→G (861Q)¹² | u |
| H2     | BG1                 | MSI-H | -                           | + hMSH2 exon6 | deletion | u |
| H5     | BG1                 | MSI-H | -                           | -                                                  |                                |
| H11    | BG1                 | MSI-H | +                           | +                                                  |                                |
| H23    | BG1                 | MSI-H | -                           | + hMSH2 exon1-6 | deletion | u |
| H25    | BG3                 | MSI-H | -                           | +                                                  |                                |
| H13    | BG1                 | MSI-H | -                           | + hMSH2 exon7 | c.1231 insertion T shift | u |
| H34    | BG4                 | MSI-H | -                           | + hMSH2 exon1-7 | deletion | u |
| H3     | BG1                 | MSI-H | +                           | - hMLH1 exon18 | c.2041G→A (A681T) | u |
| H12    | BG3                 | MSI-H | +                           | - hMLH1 exon15 | IVS15+1 G→A (SD of Exon 15) | u |
| H19    | BG1                 | MSI-H | +                           | - hMLH1 exon8 | c.677G→A (splice site mutation) | u |
| H20    | BG1                 | MSI-H | +                           | - hMLH1 exon8 | c.677G→A (splice site mutation) | u |
| H21    | BG1                 | MSI-H | +                           | - hMLH1 exon9 | c.214G→A (W714stop) | u |
| H28    | BG1                 | MSI-H | +                           | - hMLH1 exon8 | c.655A→G (219V) | m |
| H29    | BG1                 | MSI-H | +                           | - hMLH1 exon6 | c.503_4insA1 | u |
| H30    | BG1                 | MSI-H | +                           | - hMLH1 exon9 | IVS9+1 G→A (SD of Exon 9) | u |
| H14    | BG1                 | MSI-H | +                           | -                                                  |                                |
| H18    | BG1                 | MSI-H | +                           | -                                                  |                                |
| H33    | BG1                 | MSI-H | +                           | -                                                  |                                |
| H35    | BG3                 | MSI-H | +                           | - hMLH1 exon17 | c.1930 del G | u |
| H8     | BG4                 | MSI-L | +                           | +                                                  | m |
| H6     | BG3                 | MSS   | +                           | +                                                  | m |
| H36    | BG1                 | MSS   | +                           | +                                                  | u |
| H15    | BG3                 | MSS   | +                           | +                                                  | u |
| H27    | BG1                 | MSS   | +                           | +                                                  | u |

*: Expression; <: Deletion; ¹: Novel mutation discovered; ²: Polymorphism; m: Methylation; u: Non-methylation; MSI-H: High frequency microsatellite instability; MSI-L: Low frequency microsatellite instability; MSS: Microsatellite stability.

10, respectively. No loss of mismatch repair protein expression was found in the other 8 samples.
and lower expression of mismatch repair protein, increasing DNA replication errors and microsatellite instability which results in tumorigenesis\cite{18,19}. Mutations in hMSH2 and hMLH1 are most common\cite{4-6}. Therefore, we mainly studied the two genes.

Microsatellite instability detection was performed in 5 microsatellite markers, including D2S123, D5S346, BAT-25, BAT-26 and BAT-40. The MSI-H detection rate was 83.3%, demonstrating that the incidence of MSI-H is high in patients with HNPCC, and microsatellite instability is one of the most important features of HNPCC and reflects mismatch repair gene state at a certain extent. Loss of mismatch repair protein expression occurred in 88% MSI-H samples while no loss of mismatch repair protein expression occurred in MSI-L and MSS samples, indicating that the specificity, sensitiv-

![Diagram A](image1.png)
Deletion of exon 8 from hMSH2 gene in proband from number 2 family

![Diagram B](image2.png)
Deletion of exon 1-6 from hMSH2 in proband from number 22 family

![Diagram C](image3.png)
Deletion of exon 1-7 from hMSH2 in proband from number 34 family

Figure 1 Large fragment deletion results with MLPA technique. A indicates peak graph of fluorescence intensity of proband PCR products. B indicates peak graph of fluorescence intensity of control PCR products. ↓ indicates large fragment deletion in exon.
In MSI-H samples, the detection rate of micromutation in hMSH2 and hMLH1 was 56%. Micromutations of hMLH1 occurred in exons 6, 8, 9, 15, 17-19 and accounted for 64.3%. Micromutations of hMSH2 occurred in exons 3, 5, 7 and 13 and accounted for 35.7%. The mutation types included frame shift, non-sense, splicing and missense mutations. By searching the database of International Society for Gastrointestinal Hereditary Tumors (http://www.insight-group.org), we found 3 new mutational sites including a frame shift mutation at c.503_4insA in hMLH1, and a frame shift mutation at c.899_890insAT, and a splicing mutation at IVS7-1G→A, SA of exon 8 in hMSH2. Since these mutations could lead to protein product truncation, further study is needed in a larger-scale population to confirm whether such mutations only occur in the north of China. It is evident that the mutation spectrum of HNPCC mismatch repair gene in Chinese is broad and multiple.

Grabowski et al. reported that large fragment deletion in hMLH1 and hMSH2 accounts for 17% of all pathogenic mutations, which is almost consistent with the results of our study. The three types of large fragment deletion are in line with the findings reported by Nakagawa et al. Large fragment deletion commonly occurs in hMSH2, and should be reckoned with in molecular genetics of HNPCC. Therefore, detection of HNPCC molecular genetics should include large fragment deletion detection.

With the development of epigenetics in recent years, DNA methylation has gradually become a new research focus. In human genome, S' promoter of 50% genes contains a CpG region, also known as CpG island, with its length > 197 bp. CpG island is in a non-methylation state under normal circumstances. CpG island methylation may lead to loss of gene expression and replication errors. The promoter methylation of hMLH1 gene is most common in known mismatch repair genes. The detection rate of hMLH1 gene promoter methylation in our study was almost similar to the reported data. Exhaustive and partial methylations were observed in our study, demonstrating that hMLH1 gene promoter methylation may occur in patients with HNPCC, and the methylation level is different in different individuals. A deletion at c.655A→G (1219 V) in hMLH1, loss of hMLH1 protein expression, and hMLH1 gene promoter methylation were found in sample H28, suggesting that further study is needed to explore the protein expression and regulation of HNPCC pathologic mechanism.

An overview of the whole process of detection analysis of the 30 proband samples, microsatellite instability was first performed, then gene micromutation, large fragment deletion and promoter methylation were detected, respectively. The detection rate of gene micromutation was 46.7% (14/30), the detection rate of large fragment deletion detection in combination was increased to 56.7% (17/30). However, the detection rate of three methods in combination was 63.3% (19/30). Almost no comprehensive and systemic detection has been reported both at home and abroad. The detection rate in our study was higher than or similar to reported data. Multiple methods in combination may improve the detection efficiency and accuracy of HNPCC and can determine HNPCC families. In order to make early diagnosis and treatment, HNPCC family members should regularly be examined. At the same time, since gene detection is time-consuming and expensive, the cost of various tests and clinical significance should be taken into account according to the actual situation. Therefore, the detection strategy should be made in the following steps. First, families meeting the HNPCC criteria are selected, and then immunohistochemistry and microsatellite instability detection of hMLH1 and hMSH2 are performed. If both of the two detections are negative, mutation detection need not be done. If one of the two detections is positive, micromutations in hMLH1 and hMSH2 should be detected. If micromutation is not detectable, large fragment deletion detection should be considered. MLPA technique can be used in detecting large fragment deletion and is characterized by DNA probe hybridization. PCR technique is rapid, sensitive, specific, reliable and cheap. All the 35 exons of hMLH1 and hMSH2 gene can be detected in the same reaction system with MLPA technique. Epigenetics provides a new idea for the early diagnosis, treatment and prognosis of tumors. Studies indicate that CpG island methylation in the hMLH1 gene promoter region is also a mechanism underlying gene inactivation and tumorigenesis. Therefore, based on traditional micromutation detection, we should further combine large fragment deletion detection. For samples without micromutation and large fragment deletion, mismatch repair gene promoter methylation detection should be taken into account. Various detection methods in combination can better diagnose HNPCC.

**COMMENTS**

**Background**

Hereditary non-polyposis colorectal cancer (HNPCC), which is caused by a germline mutation in the mismatch repair gene or is associated with tumors exhibiting microsatellite instability (MSI), is characterized by increased risk of developing colon cancer and other cancers, such as cancers of endometrium, ovary, stomach, small intestine, hepatobiliary tract, upper urinary tract, brain, and skin. The diagnosis of HNPCC can be made based on the Amsterdam Clinical Criteria or on molecular genetic testing for germline mutations in one of the mismatch repair (MMR) genes.

Figure 2  Electropherogram of hMLH1 gene promoter methylation detection. M: Methylation; U: Non-methylation; H: Family number. H8 manifests partial methylation. H6 and H28 manifest exhaustive methylation.
Research frontiers

About 80% of HNPCC are associated with germline mutations in hMLH1 and hMSH2. Most of these mutations are micromutations that is a point mutation, small fragment insertion or deletion, etc. Large fragment deletion in hMLH1 and hMSH2 gene is another way of germline mutation. In addition, recent epigenetic researches indicate that CpG island methylation in the hMLH1 gene promoter region is also a mechanism underlying gene inactivation and tumorigenesis.

Innovations and breakthroughs

They used combined MSI and immunohistochemistry detection, gene mutation detection (i.e. sequencing and large fragment deletion detection) and methylation detection to study the characteristics of MMR gene mutation and hMLH1 gene promoter methylation in Chinese HNPCC patients. The results demonstrate that the combined MSI and immunohistochemistry detection might be used as effective screening indicators before genetic testing. Furthermore, detection of HNPCC molecular genetics should include large fragment deletion detection. For samples without micromutation and large fragment deletion, mismatch repair gene promoter methylation detection should be taken into account.

Applications

According to their results, the detection strategy should be made in the following steps. First, families meeting the HNPCC criteria are selected, and then immunohistochemistry and microsatellite instability detection of hMLH1 and hMSH2 are performed. If both of the two detections are negative, mutation detection needs not be done. If one of the two detections is positive, micromutations in hMLH1 and hMSH2 should be detected. If micromutation is not detectable, large fragment deletion detection should be considered. For samples without micromutation and large fragment deletion, mismatch repair gene promoter methylation detection should be taken into consideration. Various detection methods in combination may better diagnose HNPCC.

Peer review

The authors performed a systematic analysis of various genetic diagnostic methods in Chinese HNPCC patients and assessed their efficiency. The results are interesting and suggest that MSI, immunohistochemistry detection, gene mutation detection and methylation detection in combination may better diagnose HNPCC.

REFERENCES

1. Liu B, Parsons R, Papadopoulos N, Nicolaides NC, Lynch HT, Watson P, Jass JR, Dunlop M, Wylie A, Pelomaki P, de la Chapelle A, Hamilton SR, Vogelstein B, Kinzeler KW. Analysis of mismatch repair genes in hereditary nonpolyposis colorectal cancer patients. Nat Med 1996; 2: 169-174
2. Lynch HT. Smyrk T. Hereditary nonpolyposis colorectal cancer (Lynch syndrome). An updated review. Cancer 1996; 78: 1149-1167
3. Wagner A, Tops C, Wijnin JT, Zwinderman K, van der Meer C, Kets M, Niermeijer MF, Klijn JG, Tibbon A, Verkuijlen P, Nakagawa H, Geugien M, Jaghmohan-HF, Meijers-Heijboer H. Genetic testing in hereditary nonpolyposis colorectal cancer families with a MSH2, MLH1, or MSH6 mutation. J Med Genet 2002; 39: 833-837
4. Nyström-Lahti M, Wu Y, Moisio AL, Hofstra RM, Oisinga J, Mecklin JP, Jarvinen HJ, Leisti J, Buys CJ, de la Chapelle A, Pelomaki P. DNA mismatch repair gene mutations in 55 kindreds with verified or putative hereditary non-polyposis colorectal cancer. Hum Mol Genet 1996; 5: 763-769
5. Pelomaki P. Deficient DNA mismatch repair: a common etiologic factor for colon cancer. Hum Mol Genet 2001; 10: 735-740
6. Pelomaki P, Gao X, Mecklin JP. Genotype and phenotype in hereditary nonpolyposis colon cancer: a study of families with different vs. shared predisposing mutations. Fam Cancer 2001; 1: 9-15
7. Wagner A, Barrows A, Wijnin JT, van der Klift H, Franken PF, Verkuijlen P, Nakagawa H, Georgelin M, Jaghjohan-Changur S, Breukel C, Meijers-Heijboer H, Morreau H, van Puijjenbroek M, Burn J, Coronel S, Kinarsky Y, Okimoto R, Watson P, Lynch JF, de la Chapelle A, Lynch HT, Fodde R. Molecular analysis of hereditary nonpolyposis colorectal cancer in the United States: high mutation detection rate among clinically selected families and characterization of an American founder genomic deletion of the MSH2 gene. Am J Hum Genet 2003; 72: 1088-1100
8. Wang Y, Friedl W, Lambert C, Jungck M, Mathiak M, Pagenstecher C, Propping P, Mangold E. Hereditary nonpolyposis colorectal cancer: frequent occurrence of large genomic deletions in MSH2 and MLH1 genes. Int J Cancer 2003; 103: 636-641
9. Wijnen J, van der Klift H, Wijnin JT, van der Meijden AM, Manfro K, Tops C, Meijers-Heijboer H, Lindhout D, Muller P, Fodde R. MSH2 genomic deletions are a frequent cause of HNPCC. Nat Genet 1999; 20: 322-326
10. Jones PA, Laird PW. Cancer epigenetics comes of age. Nat Genet 1999; 21: 163-167
11. Rodriguez-Bigas MA, Boland CR, Hamilton SR, Henson DE, Jass JR, Khan PM, Lynch H, Perou M, Smyrk T, Sobin L, Svistavasta S. A National Cancer Institute Workshop on Hereditary Nonpolyposis Colorectal Cancer Syndrome: meeting highlights and Bethesda guidelines. J Natl Cancer Inst 1997; 89: 1758-1762
12. Chan TL, Chao W, Leung SY, Yuen ST. BRAF and KRAS mutations in colorectal hyperplastic polyps and serrated adenomas. Cancer Res 2003; 63: 4878-4881
13. Boland CR, Thibodeau SN, Hamilton SR, Siddransky D, Eshleman JR, Burt RW, Meltzer SJ, Rodríguez-Bigas MA, Fodde R, Ranzani GN, Svistavasta S. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998; 58: 5248-5257
14. Yuen ST, Chan TL, Ho JW, Chan AS, Chung LP, Lam PW, Tse CW, Wylie AH, Leung SY. Germline, somatic and epigenetic events underlying mismatch repair defect in colorectal and HNPCC-related cancers. Oncogene 2002; 21: 7585-7592
15. Sheng JQ, Chan TL, Chan YW, Huang JS, Chen JG, Zhang MZ, Gao XL, Mu H, Chan AS, Li SR, Yuen ST, Leung SY. Microsatellite instability and novel mismatch repair gene mutations in northern Chinese population with hereditary nonpolyposis colorectal cancer. Chin J Dig Dis 2006; 7: 197-205
16. Schouten JP, McElgunn CJ, Waaijer LM, Zijwijnburg D, Diepvens F, Pals G. Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res 2002; 30: 657
17. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methyltion-specific PCR: a novel PCR assay for methyltion status of CpG islands. Proc Natl Acad Sci USA 1996; 93: 9821-9826
18. Bocker T, Diermann J, Friedl W, Gebert J, Holinski-Feder E, Karner-Hanusch J, von Knebel-Doeberitz M, Koebke K, Moeslein G, Schackert HK, Wirtz HC, Fishel R, Ruschhoff J. Microsatellite instability analysis: a multicenter study for reliability and quality control. Cancer Res 1997; 57: 4739-4743
19. Boardman LA. Heritable colorectal cancer syndromes: recognition and preventive management. Gastroenterol Clin North Am 2002; 31: 1107-1131
20. Grabowski M, Mueller-Koch Y, Grabson-Frodl E, Koehler U, Keller G, Vogelsang H, Dietmaier W, Kopp R, Siebers U, Schmitt W, Neitzel B, Gruber M, Doerner C, Kerker B, Ruemmele F, Henke G, Holinski-Feder E. Deletions account for 17% of pathogenic germline alterations in MLH1 and MSH2 in hereditary nonpolyposis colorectal cancer (HNPCC) families. Genet Test 2005; 9: 138-146
21. Nakagawa H, Hample H, de la Chapelle A. Identification and characterization of genomic rearrangements of MSH2 and MLH1 in Lynch syndrome (HNPCC) by novel hybridization techniques. Hum Mutat 2000; 22: 285-298
22. Jubb AM, Bell SM, Quirke P. Methyltion and colorectal cancer. J Pathol 2001; 195: 111-134
23. Deng G, Chen A, Hong J, Chae HS, Kim YS. Methyltion of CpG in a small region of the hMLH1 promoter invariably
correlates with the absence of gene expression. *Cancer Res* 1999; 59: 2029-2033

24 **Hawkins** N, Norrie M, Cheong K, Mokany E, Ku SL, Meagher A, O'Connor T, Ward R. CpG island methylation in sporadic colorectal cancers and its relationship to microsatellite instability. *Gastroenterology* 2002; 122: 1376-1387

25 **Peltomaki** P, Vasen HF. Mutations predisposing to hereditary nonpolyposis colorectal cancer: database and results of a collaborative study. The International Collaborative Group on Hereditary Nonpolyposis Colorectal Cancer. *Gastroenterology* 1997; 113: 1146-1158

26 **Yuen ST**, Davies H, Chan TL, Ho JW, Bignell GR, Cox C, Stephens P, Edkins S, Tsui WW, Chan AS, Futreal PA, Stratton MR, Wooster R, Leung SY. Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia. *Cancer Res* 2002; 62: 6451-6455

27 **Haung YQ**, Yuan Y, Wang YP, Zhu M, Zhang SZ, Zheng S. [Large genomic deletions of mismatch repair genes in Chinese patients with hereditary nonpolyposis colorectal cancer] *Zhonghua Yi Xue Yi Chuan Xue Zazhi* 2005; 22: 88-90

28 **Gille JJ**, Hogervorst FB, Pals G, Wijnen JT, van Schooten RJ, Dommering CJ, Meijer GA, Craanen ME, Nederlof PM, de Jong D, McElgunn CJ, Schouten JP, Menko FH. Genomic deletions of MSH2 and MLH1 in colorectal cancer families detected by a novel mutation detection approach. *Br J Cancer* 2002; 87: 892-897

29 **Deng G**, Peng E, Gum J, Terdiman J, Sleisenger M, Kim YS. Methylation of hMLH1 promoter correlates with the gene silencing with a region-specific manner in colorectal cancer. *Br J Cancer* 2002; 86: 574-579

30 **Boland CR**, Goel A. The silence of the genes: matching mismatch repair defects with tumors. *Cancer* 2003; 98: 2091-2094